Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Wegovy and Zepbound
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on Wednesday.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
BioSpace
3h
Lilly Pumps $3B Into Wisconsin Site as Compounders Close in on Tirzepatide
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...
2d
on MSN
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
20h
Eli Lilly to spend $3 billion, add 750 employees in Kenosha County expansion
Drugmaker Eli Lilly and Co. will invest $3 billion and add 750 employees in Kenosha County as the company expands a plant it ...
2d
Lilly's tirzepatide challenges semaglutide in obesity drug market
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
18h
Lilly planning $3B expansion of Wisconsin plant to boost production
Eli Lilly (LLY) plans to boost production of its popular diabetes and weight-loss medications with a $3B expansion of its ...
STAT
1d
U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback